Scarica l'app Stockscreener
0.933
0.86%
0.0093
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ITRM Giù?
Forum
Previsione
Frazionamento azionario
Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie
Transcript : Iterum Therapeutics plcSpecial Call - MarketScreener
Research Analysts Set Expectations for ITRM FY2026 Earnings - Defense World
Two Sigma Investments LP Invests $45,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships - pharmaphorum
Citadel Advisors LLC Acquires Shares of 21,207 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics (ITRM) Partners with EVERSANA for U.S. Launc - GuruFocus
Iterum Therapeutics announces partnership with EVERSANA - PharmaLive
Iterum Therapeutics inks deal for ORLYNVAH commercialization By Investing.com - Investing.com Nigeria
Iterum Therapeutics inks deal for ORLYNVAH commercialization - Investing.com
Iterum Therapeutics Announces Partnership for Commercialization Services - Yahoo Finance
Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa
Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia
Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus
Iterum Therapeutics (ITRM) Extends $20M Payment Deadline with Pf - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note | ITRM Stock News - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note - The Manila Times
Iterum Therapeutics Announces Extension of $20 Million Regulatory Milestone Payment Deadline with Pfizer to 2029 - Nasdaq
Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan
Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 - MSN
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable? - simplywall.st
Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2025 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Stability Amidst Market Challenges - GuruFocus
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: - GuruFocus
ITRM Plans Fourth-Quarter Launch for ORLYNVAH in UTI Treatment | - GuruFocus
Iterum Therapeutics (ITRM) Projects Adequate Funding Until 2026 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
Transcript : Iterum Therapeutics plc, Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Q1 Earnings Estimate for ITRM Issued By HC Wainwright - Defense World
Iterum Therapeutics’ (ITRM) Buy Rating Reiterated at HC Wainwright - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? - Yahoo Finance
Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Monday - Defense World
Iterum Therapeutics (ITRM) Receives Buy Rating from HC Wainwrigh - GuruFocus
Iterum Therapeutics (ITRM) Receives Buy Rating from Analyst | IT - GuruFocus
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 - Yahoo Finance
Iterum Therapeutics Earnings Coming May 13: Next-Gen Antibiotics Developer Sets Q1 2025 Update - Stock Titan
Renaissance Technologies LLC Purchases Shares of 438,816 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Check Out Iterum Therapeutics Plc (ITRM)’s Trade Data Rather Than the Analysts’ Views - Sete News
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares - The Manila Times
Iterum Therapeutics Raises $5M from Single Investor: Major Push for Antibiotic Commercialization - Stock Titan
Iterum Therapeutics Plc: Rising -64.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Iterum Therapeutics Plc (ITRM) Becoming More Attractive for Investors - knoxdaily.com
Iterum Therapeutics (ITRM) Secures $5 Million in Direct Offering - GuruFocus
Evaluating ITRM’s financial ratios for a profitable investment - uspostnews.com
Iterum Therapeutics secures $5 million in direct offering - Investing.com
Iterum Therapeutics Announces $5 Million Registered Direct Offering Of Ordinary Shares - marketscreener.com
Iterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of Shares - Nasdaq
Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate - Stock Titan
ITRM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Iterum Therapeutics Plc (NASDAQ:ITRM) Shares Surged 24.11% In A Week – But Can It Maintain Its Gains? - Marketing Sentinel
1.80%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):